Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1832526 (
PCC
)
5,967
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The second and third modules of human
decay accelerating factor
(
DAF
) are necessary and sufficient to accelerate decay of the classical pathway (CP) convertase of complement. No structure of a mammalian protein with decay-accelerating activity has been available to date. We therefore determined the solution structure of
DAF
modules 2 and 3 (
DAF
approximately 2,3). Structure-guided analysis of 24 mutants identified likely contact points between
DAF
and the CP convertase. Three (R96, R69, and a residue in the vicinity of L171) lie on
DAF
approximately 2,3's concave face. A fourth, consisting of K127 and nearby R100, is on the opposite face. Regions of module 3 remote from the semiflexible 2-3 interface seem not to be involved in binding to the CP convertase.
DAF
thus seems to occupy a groove on the CP convertase such that both faces of
DAF
close to the 2-3 junction (including a positively charged region that encircles the protein at this point) interact simultaneously. Alternative pathway convertase interactions with
DAF
require additional regions of
CCP
3 lying away from the 2-3 interface, consistent with the established additional requirement of module 4 for alternative pathway regulation.
...
PMID:Solution structure of a functionally active fragment of decay-accelerating factor. 1267 58